现代医药卫生
現代醫藥衛生
현대의약위생
MODERN MEDICINE HEALTH
2015年
9期
1292-1294
,共3页
钙代谢障碍%磷/代谢%肾透析%尿毒症%营养状况%血管钙化
鈣代謝障礙%燐/代謝%腎透析%尿毒癥%營養狀況%血管鈣化
개대사장애%린/대사%신투석%뇨독증%영양상황%혈관개화
Calcium metabolism disorders%Phosphorus/metabolism%Renal fialysis%Uremia%Nutritional status%Vascular calcification
目的：观察低钙透析液联合高通量血液透析对改善尿毒症患者钙磷指标及血管钙化的临床疗效。方法选择2011年3月至2014年3月在该院行维持性血液透析患者48例，分为低钙透析液联合高通量血液透析（低钙联合 HFHD 组）、高通量血液透析组（HFHD 组）和普通血液透析组（HD 组），其中低钙联合 HFHD 组患者采用1.25 mmol/L钙离子浓度的低钙透析液，比较各组治疗前及治疗12个月后透前血钙、血磷、钙磷乘积及X射线腹主动脉钙化评分等指标。结果低钙联合HFHD组治疗12个月后血磷、钙磷乘积水平及血管钙化评分较治疗前下降，骨化三醇服用量减少，差异均有统计学意义（P<0.05），低钙联合HFHD组与HFHD组比较，差异均有统计学意义（P<0.05）。HD组患者治疗后各项指标与治疗前比较，差异均无统计学意义（P>0.05）。结论低钙透析液联合HFHD能有效改善高磷血症、降低钙磷乘积及血管钙化评分，减少骨化三醇用量，提高尿毒症患者生存质量。
目的：觀察低鈣透析液聯閤高通量血液透析對改善尿毒癥患者鈣燐指標及血管鈣化的臨床療效。方法選擇2011年3月至2014年3月在該院行維持性血液透析患者48例，分為低鈣透析液聯閤高通量血液透析（低鈣聯閤 HFHD 組）、高通量血液透析組（HFHD 組）和普通血液透析組（HD 組），其中低鈣聯閤 HFHD 組患者採用1.25 mmol/L鈣離子濃度的低鈣透析液，比較各組治療前及治療12箇月後透前血鈣、血燐、鈣燐乘積及X射線腹主動脈鈣化評分等指標。結果低鈣聯閤HFHD組治療12箇月後血燐、鈣燐乘積水平及血管鈣化評分較治療前下降，骨化三醇服用量減少，差異均有統計學意義（P<0.05），低鈣聯閤HFHD組與HFHD組比較，差異均有統計學意義（P<0.05）。HD組患者治療後各項指標與治療前比較，差異均無統計學意義（P>0.05）。結論低鈣透析液聯閤HFHD能有效改善高燐血癥、降低鈣燐乘積及血管鈣化評分，減少骨化三醇用量，提高尿毒癥患者生存質量。
목적：관찰저개투석액연합고통량혈액투석대개선뇨독증환자개린지표급혈관개화적림상료효。방법선택2011년3월지2014년3월재해원행유지성혈액투석환자48례，분위저개투석액연합고통량혈액투석（저개연합 HFHD 조）、고통량혈액투석조（HFHD 조）화보통혈액투석조（HD 조），기중저개연합 HFHD 조환자채용1.25 mmol/L개리자농도적저개투석액，비교각조치료전급치료12개월후투전혈개、혈린、개린승적급X사선복주동맥개화평분등지표。결과저개연합HFHD조치료12개월후혈린、개린승적수평급혈관개화평분교치료전하강，골화삼순복용량감소，차이균유통계학의의（P<0.05），저개연합HFHD조여HFHD조비교，차이균유통계학의의（P<0.05）。HD조환자치료후각항지표여치료전비교，차이균무통계학의의（P>0.05）。결론저개투석액연합HFHD능유효개선고린혈증、강저개린승적급혈관개화평분，감소골화삼순용량，제고뇨독증환자생존질량。
Objective To observe the clinical curative effect of low calcium dialysate combined with high flux hemodial-ysis on improving uremia patients with calcium phosphate indicators and vascular calcification. Methods A total of 48 patients with maintenance hemodialysis in this hospital from March 2011 to March 2014 were selected and divided into low calcium dialysate combined with high flux hemodialysis group(the low calcium+HFHD group),high flux hemodialysis group(HFHD group), the ordinary dialysis(HD group),in which,the low calcium+HFHD group adopted 1.25 mmol/L calciumion concentration of car-bonate with low calcium dialysate. It was compared inserum phosphorus ,the calcium-phosphorus products and X-ray abdominal aortic calcification score between these groups before and after treatment 12 months. Results After 12-month treatment,the low calcium+HFHD group was lower in serum phosphate ,calcium-phosphorus product and vascular calcification score than those be-fore the treatment,as well as less in dosage of calcitriol than that before for the treatment. The difference had statistical significance (P<0.05). There were statistical significance in difference between the low calcium+HFHD group and HFHD group (P<0.05). All the indicators in HD group before the treatment had no statistical significance compared to those after the treatment (P>0.05). Conclusion It is effective to improve hyperphosphatemia and reduce the calcium-phosphorus product and vascular calcification scoreunder calcium dialysate combined with high flux hemodialysis to reduce the dosage of calcitriol ,improve the quality of ure-mia patients survival.
